C
Cohera Medical
Surgical adhesives and sealants for application and procedures in surgery
About Cohera Medical
Cohera Medical, established in 2006 as a spin-out from the University of Pittsburgh, operated as a medical device company focused on developing and commercializing absorbable surgical adhesives and sealants. The company was founded by Dr. Eric Beckman, a professor of engineering at the University of Pittsburgh, and Dr. Michael Buckley, then an oral surgeon at the university's School of Dental Medicine. The core technology emerged accidentally from their research on a tissue regeneration membrane, leading to the creation of a biocompatible adhesive. Patrick Daly joined as President and CEO in 2006, leading the company through significant fundraising and product development milestones. Cohera Medical ultimately declared bankruptcy in October 2018.
The company's business was centered on providing surgeons with alternatives to traditional wound closure methods like sutures and staples, aiming to reduce post-operative complications. Its primary clients were surgeons and hospitals, particularly in the fields of plastic and general surgery. Revenue was generated through the sale of its surgical adhesive products. The company secured substantial private investment, raising $136 million over 16 funding rounds to support its clinical trials and commercialization efforts.
Cohera Medical's flagship product was TissuGlu® Surgical Adhesive, a resorbable, non-toxic adhesive designed for internal use. TissuGlu was developed to bond tissue layers together in large flap surgeries, such as abdominoplasties (tummy tucks), to reduce the accumulation of fluid and the need for post-surgical drains. The adhesive, a polyurethane-based formula, is applied as a liquid and cures into a flexible solid upon contact with water in the patient's tissue. TissuGlu received CE Marking approval in the European Union in 2011 and was subsequently launched in Germany. In February 2015, it became the first tissue adhesive for internal use to receive FDA approval in the United States.
The company also developed Sylys® Surgical Sealant, a synthetic, resorbable sealant created to reduce anastomotic leakage in intestinal and colorectal surgeries. This product was designed to reinforce the suture or staple line during the critical initial days of healing. Sylys obtained a CE Mark in Europe and was designated for the Expedited Access Pathway by the FDA, highlighting the clinical need for such a device. Cohera had established a distribution agreement with Terumo Corporation to market Sylys in Japan.
Source: Dealroom company dataNews
Open roles
Cohera Medical in the Raleigh ecosystem
The Cohera Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Bradford Capital Partners
- KCKern Whelan Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cohera Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cohera Medical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

